ClevelandDx key facts
as of Oct 2026- Developer of a blood-based cancer diagnostics platform designed to improve clarity in disease detection.
- ClevelandDx is valued at approximately $285.2M as of Oct 2026 (last reported valuation).
- It has raised $126.1M; the latest was Later Stage VC ($14.4M) in Oct 2025.
- Notable investors include Novo Holdings, Jumpstart Ventures, JobsOhio Ventures, LYFE Capital, Cleveland Clinic Ventures — 8 tracked in total.
- Status: Privately Held (backing).
ClevelandDx's last reported valuation, Oct 2025. Nothing priced has surfaced since.
- ·Watch ClevelandDx: the Monday email on marks, rounds and moves
ClevelandDx funding rounds
No funding rounds for ClevelandDx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
ClevelandDx valuation
ClevelandDx's last reported valuation was $285 million in Oct 2025. No priced round, secondary trade or fund mark has surfaced since.
ClevelandDx investors
8 investors are on record for ClevelandDx, including Novo Holdings, Jumpstart Ventures, JobsOhio Ventures and LYFE Capital.
About ClevelandDx
Developer of a blood-based cancer diagnostics platform designed to improve clarity in disease detection. The company offers the IsoPSA test for prostate cancer, built on its IsoClear platform that measures structural differences in proteins, enabling physicians to reduce unnecessary biopsies and better identify high-grade disease risk.
- Sector
- Healthcare
- HQ
- Cleveland, OH, United States
- Founded
- 2013
- Employees
- 89
- Website
- clevelanddx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.